Twist Bioscience Corp (TWST) legal chief sells 14,205 shares under plan

Rhea-AI Filing Summary

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 14,205 shares of common stock on August 5, 2026 at an average price of $109.75 per share. The sale was executed in an open market or private transaction under a pre‑arranged Rule 10b5-1 trading plan adopted on February 17, 2026.

Following this transaction, Cho directly owns 89,866 Twist Bioscience shares.

Insider Trade Summary 10b5-1

Net Seller: 14,205 shares

Net Sell 1 txn

Insider Cho Dennis

Role See Remarks

Sold 14,205 shs ($1.56M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	14,205	$109.75	$1.56M

Holdings After Transaction: Common Stock — 89,866 shares (Direct)

Footnotes (1)

1. F1. The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 17, 2026.

Key Figures

Shares sold: 14205.0000 shares Sale price: 109.7500 per share Shares owned after transaction: 89866.0000 shares +1 more

4 metrics

Shares sold 14205.0000 shares Common stock sold by Dennis Cho on August 5, 2026

Sale price 109.7500 per share Average price for the August 5, 2026 sale

Shares owned after transaction 89866.0000 shares Direct holdings of Dennis Cho following the sale

10b5-1 plan adoption date February 17, 2026 Date Dennis Cho adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, open market or private transaction

2 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported is effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction regulatory

"Transaction code description: Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 04:06 PM Accepted by SEC EDGAR 08/07/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What insider transaction did TWST report for executive Dennis Cho?

Dennis Cho sold 14,205 shares of Twist Bioscience common stock on August 5, 2026 at $109.75 per share, leaving him with 89,866 directly owned shares after the transaction.

Was the Dennis Cho TWST share sale made under a Rule 10b5-1 plan?

Yes. The sale of 14,205 shares by Dennis Cho was effected pursuant to a Rule 10b5-1 trading plan that he previously adopted on February 17, 2026.

How many TWST shares does Dennis Cho hold after this reported sale?

After the August 5, 2026 sale, Dennis Cho directly holds 89,866 shares of Twist Bioscience common stock, as reported in the insider transaction filing.

What price did Dennis Cho receive for his TWST shares in the August 2026 sale?

Dennis Cho’s August 5, 2026 transaction reported a sale of 14,205 shares of Twist Bioscience common stock at an average price of $109.75 per share in an open market or private transaction.

What is Dennis Cho’s role at Twist Bioscience (TWST)?

Dennis Cho serves as Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, according to the insider transaction disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Dennis

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/05/2026		S		14,205(1)	D	$109.75	89,866	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 17, 2026.

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)